Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Advanced Soft Tissue Sarcoma
NCT00413192Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2007
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of eribulin in soft tissue sarcoma (STS), sponsored by Eisai Co., Ltd. Primary endpoint: Progression Free Survival at 12 Weeks. Started Jan 2007; status: completed.
02
Drugs
eribulin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00413192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413192.